Stanley J. Meresman Sells 10,000 Shares of Guardant Health Inc (NASDAQ:GH) Stock

Guardant Health Inc (NASDAQ:GH) Director Stanley J. Meresman sold 10,000 shares of Guardant Health stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $77.99, for a total value of $779,900.00. Following the sale, the director now directly owns 11,302 shares of the company’s stock, valued at $881,442.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ:GH traded down $0.33 on Thursday, reaching $78.83. The company’s stock had a trading volume of 648,900 shares, compared to its average volume of 1,091,737. Guardant Health Inc has a 1-year low of $32.33 and a 1-year high of $112.21. The firm has a market cap of $7.51 billion and a PE ratio of -28.15. The business’s 50-day moving average price is $68.42 and its two-hundred day moving average price is $80.90.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.25. Guardant Health had a negative return on equity of 11.70% and a negative net margin of 40.99%. The firm had revenue of $60.85 million during the quarter, compared to analysts’ expectations of $45.40 million. During the same period in the previous year, the firm earned ($1.94) earnings per share. The company’s revenue was up 180.4% on a year-over-year basis. As a group, equities research analysts forecast that Guardant Health Inc will post -0.88 earnings per share for the current fiscal year.

GH has been the subject of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Friday, November 8th. Zacks Investment Research raised Guardant Health from a “hold” rating to a “strong-buy” rating and set a $84.00 price objective for the company in a research note on Tuesday, November 12th. ValuEngine raised Guardant Health from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Canaccord Genuity reissued a “buy” rating and issued a $125.00 target price on shares of Guardant Health in a research note on Friday, November 8th. Finally, Cowen set a $110.00 target price on Guardant Health and gave the company a “buy” rating in a research note on Wednesday, August 7th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $107.60.

Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA acquired a new position in Guardant Health in the second quarter valued at about $250,000. Coatue Management LLC acquired a new position in shares of Guardant Health during the second quarter worth about $103,251,000. Commonwealth Equity Services LLC boosted its position in shares of Guardant Health by 47.9% during the second quarter. Commonwealth Equity Services LLC now owns 5,812 shares of the company’s stock worth $501,000 after buying an additional 1,883 shares during the period. Advantage Investment Management LLC boosted its position in shares of Guardant Health by 200.0% during the second quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock worth $39,000 after buying an additional 300 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Guardant Health by 102.4% during the second quarter. JPMorgan Chase & Co. now owns 83,405 shares of the company’s stock worth $7,020,000 after buying an additional 42,193 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Featured Story: Stock Symbol

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.